Home / Intelligence / Webinars / The NRDL Conundrum: Balancing Between Access and Pricing for Innovation
Available On Demand
What key insights emerged from the 2024 China National Reimbursement Drug List (NRDL) negotiations and how can they inform strategic go-to-market planning for innovative therapies?
In the 2024 NRDL negotiations, only 28% of submitted products passed expert review, significantly raising the bar for entering pricing negotiations. However, products with robust clinical differentiation or superiority can achieve price premiums over benchmarks.
Looking ahead, a recent policy to establish a Category C drug list is energizing the pharma industry, potentially providing coverage through government-guided commercial insurance for high-cost, innovative products not included in the NRDL.
In this webinar, Trinity Life Sciences’ Value, Access and Pricing experts will evaluate the impact of the value-rating system on NRDL negotiations, explore successful outcomes across therapeutic areas and introduce potential commercial pathways to inform strategic go-to-market planning for novel therapies.
Key Topics
- Overview of the 2024 China NRDL update: Changes, trends and outcomes
- Case studies across oncology, rare diseases and chronic conditions: Learnings from successful products
- Introduce the Category C and potential commercial access in the future
- Recommendation and outlook for future China pricing and access opportunities
Featuring
Max Hunt
Partner,
Value, Access & Pricing
Wenting Zhang
Director,
Evidence, Value, Access & Pricing
Allen Liu
Senior Consultant & APAC Expert,
Strategic Advisory
Rya Zhang
Consultant,
Value, Access & Pricing
Complete the form below to view the on-demand webinar
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]
Read More
Blog
5 Key Trends in Global Market Access
Key impacts on the market access and payer environment are beginning to unfold from policies enacted in 2023 and new policies enacted in 2024. To gather insights into the latest trends, Trinity Life Sciences conducted interviews with key stakeholders across various pricing and market access landscapes. Trinity is closely monitoring the evolving global advanced therapeutics […]
Read More